AI In Cancer Diagnostics Market To Reach $996.12 Million By 2030

AI In Cancer Diagnostics Market Growth & Trends

The global AI in cancer diagnostics market size is estimated to reach USD 996.12 million by 2030, registering to grow at a CAGR of 24.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing need for lowering healthcare costs, the rising importance of big data in healthcare, improving adoption of precision medicine, and declining hardware costs are key factors driving the growth.

The increasing scope of applications of artificial intelligence (AI) in various healthcare fields, including diagnostics; the rising prevalence of cancer; and the growing shortage of public health workforce are some of the key factors anticipated to fuel the adoption of artificial intelligence (AI) in cancer diagnostics over the forecast period. In addition, the increasing applicability of AI-based tools in cancer care and the rise in venture capital investments is further driving the surge in demand for this technology.

The presence of prominent players in the market such as Microsoft, Flatiron, Therapixel, and Tempus, is anticipated to positively impact the growth. These players are adopting strategies such as acquisitions, collaborations, expansions, and new product launches to increase the reach of their products in the industry and increase the availability of their products & services in diverse geographical areas. For instance, in December 2021, Microsoft announced a partnership with CVS Health to develop innovative solutions for patients to improve their health while empowering healthcare professionals with tools to better service patients.

Furthermore, the rising government support in the form of funding and initiatives for the development of healthcare infrastructure is anticipated to drive the demand for technologically advanced and cost-efficient devices over the forecast period.

 Request a free sample copy or view report summary: AI In Cancer Diagnostics Market Report

AI In Cancer Diagnostics Market Report Highlights

• Based on component, the software solutions segment dominated the market with a revenue share of 44.39% in 2024 and is expected to witness the fastest growth rate during the forecast period. 

• Based on cancer type, breast cancer had a significant revenue share of 19.41% in 2024. 

• Hospital segment dominated the market with the largest revenue share of 56.95% in 2024.

• North America AI in cancer diagnostics market dominated in 2023 with the largest share of 54.74%.

AI In Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global AI in cancer diagnostics market based on component, cancer type, end-use, and region:

AI In Cancer Diagnostics Component Outlook (Revenue, USD Million, 2018 - 2030)

• Software Solutions

• Hardware

• Services

AI In Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

• Breast Cancer

• Lung Cancer

• Prostate Cancer

• Colorectal Cancer

• Brain Tumor

• Others

AI In Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Surgical Centers and Medical Institutes

• Others

AI In Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the AI In Cancer Diagnostics Market

• EarlySign

• Cancer Center.ai

• Microsoft

• FLATIRON HEALTH

•  PathAI, Inc.

• Therapixel

• Tempus AI, Inc.

• Paige AI Inc.

• Kheiron Medical Technologies Limited

• SkinVision